Standout Papers

Cardia: study design, recruitment, and some characteristics of the examined subjects 1988 2026 2000 2013 1.3k
  1. Cardia: study design, recruitment, and some characteristics of the examined subjects (1988)
    Gary Friedman, Gary Cutter et al. Journal of Clinical Epidemiology
  2. Development of a multiple sclerosis functional composite as a clinical trial outcome measure (1999)
    Gary Cutter Brain
  3. Individual and Combined Effects of Age, Breast Density, and Hormone Replacement Therapy Use on the Accuracy of Screening Mammography (2003)
    Patricia A. Carney, Diana L. Miglioretti et al. Annals of Internal Medicine
  4. The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment (1999)
    Jill S. Fischer, Richard A. Rudick et al. Multiple Sclerosis Journal
  5. The prevalence of MS in the United States (2019)
    Mitchell T. Wallin, William J. Culpepper et al. Neurology
  6. Initial Acquisition of Mutans Streptococci by Infants: Evidence for a Discrete Window of Infectivity (1993)
    P.W. Caufield, Gary Cutter et al. Journal of Dental Research
  7. The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review (2015)
    Ruth Ann Marrie, Stephen C. Reingold et al. Multiple Sclerosis Journal
  8. Natural History of Multiple Sclerosis Symptoms (2013)
    Ilya Kister, Tamar Bacon et al. International Journal of MS Care
  9. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview (2015)
    Ruth Ann Marrie, Jeffrey A. Cohen et al. Multiple Sclerosis Journal
  10. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis (2021)
    Amber Salter, Robert J. Fox et al. JAMA Neurology
  11. Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region (2023)
    Michael Hittle, William J. Culpepper et al. JAMA Neurology

Immediate Impact

1 by Nobel laureates 3 from Science/Nature 76 standout
Sub-graph 1 of 21

Citing Papers

Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
2025 Standout
The pathogenesis of Parkinson's disease
2024 Standout
2 intermediate papers

Works of Gary Cutter being referenced

Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
2023
Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease
2021
and 1 more

Author Peers

Author Last Decade Papers Cites
Gary Cutter 13234 5519 3802 3971 756 33.9k
Michael McDermott 3050 6276 2394 3569 619 32.9k
Miguel A. Hernán 4105 3224 2941 2706 309 40.5k
Dirk L. Knol 4283 2076 1321 1542 305 35.2k
Giuseppe Remuzzi 4816 1520 4459 10816 1.3k 92.7k
Richard A. Deyo 20773 963 2495 2705 400 64.4k
Julie E. Buring 6112 1470 3467 3838 596 64.0k
Peter C. O’Brien 3644 9342 2290 2755 424 38.9k
L. Adrienne Cupples 2655 1826 2277 2222 536 42.3k
Martha S. Linet 4936 1038 4856 2528 381 25.2k
Diederick E. Grobbee 4365 1307 2754 9332 926 62.4k

All Works

Loading papers...

Rankless by CCL
2026